ArticleFrontiers in cardiovascular medicine2025
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The majority of myocardial infarction (MI) cases occur due to plaque rupture in the context of atherosclerosis (AS). This study aimed to elucidate the mechanisms underlying the effect of Methods: Apolipoprotein E-deficient mice were divided into four groups of 11. Mice in the Control and MI groups were fed a normal diet for 24-weeks, while mice in the AS + MI group were fed a high-fat diet (HFD) and mice in the AS + MI + HAL group were fed HFD supplemented with 5% HAL powder. After 23 weeks, the mice in the MI, AS + MI and AS + MI + HAL groups underwent coronary artery ligation to induce MI. A week post-ligation, 6 surviving mice were randomly selected from each group for the subsequent experiments, echocardiography was performed, followed by analysis of aortic plaque and myocardial tissue to explore potential mechanisms. Results: HAL intervention attenuated cardiac remodeling and dysfunction induced by MI, reduced inflammatory cell infiltration and fibrosis in the myocardium, and consequently improved cardiac function. HAL alleviated the inflammatory response by reducing serum concentrations and myocardial expression of interleukin-1β, interleukin-6 and tumor necrosis factor-α. Furthermore, Western blotting analysis demonstrated that HAL reduced nuclear factor-κB (NF-κB) expression. HAL also enhanced superoxide dismutase and glutathione peroxidase levels while suppressing malondialdehyde and myeloperoxidase levels in cardiac infarction tissue. Conclusion: Our data indicated that HAL attenuates cardiac remodeling by inhibiting inflammation and reducing oxidative stress. These findings provide novel insights into the effects and mechanisms of HAL in the context of MI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.